The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells

被引：10

作者：

Abeykoon, Jithma P. ^{[1
]}

Paludo, Jonas ^{[1
]}

Nowakowski, Kevin E. ^{[1
]}

Stenson, Mary J. ^{[1
]}

King, Rebecca L. ^{[2
]}

Wellik, Linda E. ^{[1
]}

Wu, Xiaosheng ^{[1
]}

Witzig, Thomas E. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN 55905 USA

[2] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA

来源：

BLOOD CANCER JOURNAL | 2019年 / 9卷 / 3期

关键词：

NUCLEAR EXPORT; KAPPA-B;

D O I：

10.1038/s41408-019-0188-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：4

共 12 条

[1] Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma [J].

Bahlis, Nizar J. ;

Sutherland, Heather ;

White, Darrell ;

Sebag, Michael ;

Lentzsch, Suzanne ;

Kotb, Rami ;

Venner, Christopher P. ;

Gasparetto, Cristina ;

Del Col, Aldo ;

Neri, Paola ;

Reece, Donna ;

Kauffman, Michael ;

Shacham, Sharon ;

Unger, T. J. ;

Jeha, Jacqueline ;

Saint-Martin, Jean-Richard ;

Shah, Jatin ;

Chen, Christine .

BLOOD, 2018, 132 (24) :2546-2554

[2] Selective inhibitors of nuclear export (SINE) in hematological malignancies [J].

Das A. ;

Wei G. ;

Parikh K. ;

Liu D. .

Experimental Hematology & Oncology, 4 (1)

[3] Structural basis for leucine-rich nuclear export signal recognition by CRM1 [J].

Dong, Xiuhua ;

Biswas, Anindita ;

Sueel, Katherine E. ;

Jackson, Laurie K. ;

Martinez, Rita ;

Gu, Hongmei ;

Chook, Yuh Min .

NATURE, 2009, 458 (7242) :1136-U71

[4] KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia [J].

Etchin, Julia ;

Sanda, Takaomi ;

Mansour, Marc R. ;

Kentsis, Alex ;

Montero, Joan ;

Le, Bonnie T. ;

Christie, Amanda L. ;

McCauley, Dilara ;

Rodig, Scott J. ;

Kauffman, Michael ;

Shacham, Sharon ;

Stone, Richard ;

Letai, Anthony ;

Kung, Andrew L. ;

Look, A. Thomas .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 (01) :117-127

[5] Aberrant NF-κB signaling in lymphoma:: mechanisms, consequences, and therapeutic implications [J].

Jost, Philipp J. ;

Ruland, Juergen .

BLOOD, 2007, 109 (07) :2700-2707

[6]

KASHYAP T, 2016, BLOOD, V128

[7]

Kashyap Trinayan, 2018, Oncotarget, V9, P30773, DOI 10.18632/oncotarget.25637

[8] Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death [J].

Kashyap, Trinayan ;

Argueta, Christian ;

Aboukameel, Amro ;

Unger, Thaddeus John ;

Klebanov, Boris ;

Mohammad, Ramzi M. ;

Muqbil, Irfana ;

Azmi, Asfar S. ;

Drolen, Claire ;

Senapedis, William ;

Lee, Margaret ;

Kauffman, Michael ;

Shacham, Sharon ;

Landesman, Yosef .

ONCOTARGET, 2016, 7 (48) :78883-78895

[9] XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB [J].

Ming, Mei ;

Wu, Wenjun ;

Xie, Bingqing ;

Sukhanova, Madina ;

Wang, Weige ;

Kadri, Sabah ;

Sharma, Shruti ;

Lee, Jimmy ;

Shacham, Sharon ;

Landesman, Yosef ;

Maltsev, Natalia ;

Lu, Pin ;

Wang, Y. Lynn .

MOLECULAR CANCER THERAPEUTICS, 2018, 17 (12) :2564-2574

[10] Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IκB and Downregulation of Survivin [J].

Nair, Jayasree S. ;

Musi, Elgilda ;

Schwartz, Gary K. .

CLINICAL CANCER RESEARCH, 2017, 23 (15) :4301-4311

← 1 2 →